This part definitely feels very broken to me. People going for clinical trials are often somewhat desperate, giving them that extra uncertainty to play with doesn't help.
This part definitely feels very broken to me. People going for clinical trials are often somewhat desperate, giving them that extra uncertainty to play with doesn't help.
The truth is there is also a lot of arbitrariness. For example, brain mets are often used as an exclusionary factor for studies, because, although a drug is evaluating mets as part of asking "will this drug work for cancer throughout the body?" a drug company will LATER have a study that focuses on whether it works on brain mets, thus excluding a huge swatch of patients. If a cancer tends to met to the brain, it really doesn't need a different study. It needs to include real-world patient populations. But that's because the studies are meant to get a drug to market.
I feel strongly that policies need to change. The FDA plays a big role in making the process problematic (a longer point for another time), but, curiously, the NIH actually is one of the most functional (for patients) research centers.